CBD seems to have an almost identical pharmacological profile to that of other antipsychotic drugs. This has been seen using behavioural and neuro chemical techniques in animal models. CBD has prevented human experimental psychosis and has been effective in open case reports and clinical trials in patients with schizophrenia. Moreover CBD has an excellent safety profile. The antipsychotic effects of CBD in relation to the psychotomimetic effects of Δ(9)-THC involve parts the brain traditionally associated with psychosis. The antipsychotic properties of CBD are still not fully understood however there is sufficient evidence to support further study. CBD is certainly an option in the treatment of psychosis in general and in schizophrenia, in particular.
CBD (Cannabidiol) is a potential treatment for psychosis. CBD enhances anandamide signaling and greatly reduces psychotic symptoms of schizophrenia.